Latest guidelines for management of DM
Reading File
Finding Sources
Finding Sources
The internal medicine and family medicine sources look most comprehensive. Let me read the most relevant sections in parallel.
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content. Let me synthesize a thorough response from the retrieved textbook material (Harrison's Internal Medicine and emergency medicine sources).
Management of Diabetes Mellitus — Current Guidelines
(Sources: Harrison's Principles of Internal Medicine, 21e; Tintinalli's Emergency Medicine)
1. Goals of Therapy
The overarching goals for all forms of DM are:
- Eliminate symptoms related to hyperglycemia
- Reduce or eliminate long-term microvascular and macrovascular complications
- Allow the patient to achieve as normal a lifestyle as possible
This is best achieved through a multidisciplinary team — primary care physician/endocrinologist, advanced practice provider, pharmacist, certified diabetes educator, nutritionist, behavioral health professional, and relevant subspecialists (ophthalmology, nephrology, cardiology, podiatry, neurology).
2. Glycemic Targets
| Parameter | General Target | Notes |
|---|---|---|
| HbA1c | < 7% | Individualized; < 6.5% in young, newly diagnosed with no CVD; < 8% in elderly/frail/frequent hypoglycemia |
| Fasting plasma glucose | 4.4–7.2 mmol/L (80–130 mg/dL) | |
| Peak postprandial glucose | < 10 mmol/L (< 180 mg/dL) | 1–2 h after meals |
| Time-in-range (TIR) | > 70% | 3.9–10 mmol/L using CGM |
Key principle: Targets are individualized based on age, comorbidities, hypoglycemia risk, disease duration, patient preference, and available resources.
3. Comprehensive Ongoing Care (Surveillance Schedule)
| Domain | Frequency |
|---|---|
| HbA1c | Every 3 months if not at goal; every 6 months if stable |
| Blood pressure | Every visit (2–4×/year) |
| Lipids | 1–2×/year |
| Dilated retinal exam | Annually (or biannually if stable) |
| Foot examination | 1–2×/year by provider; daily by patient |
| Neuropathy screening | Annually |
| Diabetic kidney disease (urine ACR + eGFR) | Annually |
| Dental examination | Twice yearly |
| Immunizations | Influenza, pneumococcal, hepatitis B, COVID-19, RSV (>60 years) |
| Screening for fatty liver disease | If risk factors present (type 2 DM/prediabetes) |
4. Lifestyle Management (Cornerstone for All DM)
Nutrition (Medical Nutrition Therapy — MNT)
- No single ideal diet exists; multiple patterns effective: Mediterranean, DASH, plant-based, low-carbohydrate, low-fat
- Limit simple sugars, fructose, and refined carbohydrates
- Reduce saturated fat; increase dietary fiber
- Weight loss targeted in overweight/obese type 2 DM — even 5% weight loss improves glycemic control
- Caloric deficit of 500–750 kcal/day recommended for weight loss
Physical Activity
- ≥ 150 min/week of moderate-intensity aerobic exercise (e.g., brisk walking)
- Resistance training 2–3×/week
- Avoid prolonged sedentary periods (break every 30 minutes)
- In type 1 DM, balance exercise with carbohydrate intake and insulin adjustments
Psychosocial Care
- Routine screening for depression, anxiety, diabetes distress, disordered eating
- Behavioral health professional involvement when needed
Diabetes Self-Management Education and Support (DSMES)
- Provided at diagnosis, annually, when goals not met, and at life transitions
- Topics: CGM/BGM use, insulin administration, hypoglycemia prevention, foot care, sick-day management
5. Pharmacologic Treatment
Type 2 DM — Step-wise Approach
Step 1 — First-line:
| Drug | Mechanism | Notes |
|---|---|---|
| Metformin | ↓ hepatic glycogenolysis/gluconeogenesis, ↑ insulin sensitivity | First-line; no weight gain, low cost, no hypoglycemia; lowers HbA1c by ~1.5%; contraindicated if eGFR < 30 |
Step 2 — Add second agent (if HbA1c target not met after 3 months, or at initiation in HbA1c ≥ 9%):
Selection guided by comorbidities:
| Comorbidity | Preferred Add-on |
|---|---|
| Established ASCVD or high CV risk | GLP-1 RA (liraglutide, semaglutide) or SGLT-2 inhibitor (empagliflozin, canagliflozin) |
| Heart failure (HFrEF) | SGLT-2 inhibitor (empagliflozin, dapagliflozin) |
| Chronic kidney disease | SGLT-2 inhibitor (if eGFR ≥ 20–25); GLP-1 RA |
| Need for weight loss | GLP-1 RA or SGLT-2 inhibitor |
| Minimize hypoglycemia | DPP-4 inhibitor, GLP-1 RA, SGLT-2 inhibitor |
| Cost constraints | Sulfonylurea or thiazolidinedione |
Drug Class Summary
| Class | Examples | Key Features |
|---|---|---|
| Biguanides | Metformin | First-line; GI side effects; lactic acidosis risk |
| Sulfonylureas | Glipizide, glimepiride | ↑ insulin secretion; hypoglycemia risk; weight gain |
| Thiazolidinediones (TZD) | Pioglitazone, rosiglitazone | Insulin sensitizers; fluid retention; fracture risk; avoid in HF |
| DPP-4 inhibitors | Sitagliptin, saxagliptin | Weight neutral; once daily; no hypoglycemia |
| GLP-1 receptor agonists | Liraglutide, semaglutide, dulaglutide | Weight loss, CV benefit, GI side effects; injectable (or oral semaglutide) |
| SGLT-2 inhibitors | Empagliflozin, dapagliflozin, canagliflozin | Glycosuria; CV and renal protection; risk of DKA, UTI, genital infections |
| Meglitinides | Repaglinide, nateglinide | Postprandial insulin ↑; take with meals |
| α-Glucosidase inhibitors | Acarbose | ↓ carbohydrate absorption; GI side effects |
| Insulin | See below | Required in type 1 DM; used in type 2 when oral agents insufficient |
6. Insulin Therapy
Type 1 DM
- Insulin is mandatory
- Preferred regimen: Basal-bolus (multiple daily injections) or Continuous Subcutaneous Insulin Infusion (CSII/pump)
- Basal: Long-acting (glargine, detemir, degludec) — once or twice daily
- Bolus: Rapid-acting (lispro, aspart, glulisine) — with each meal
- Closed-loop systems (sensor-augmented pumps / hybrid closed-loop) increasingly recommended — automate basal delivery based on CGM readings
Type 2 DM
- Consider insulin when:
- HbA1c > 10% at presentation
- Symptomatic hyperglycemia
- Failure of oral/injectable agents
- Start with basal insulin (glargine or detemir, 10 units/day or 0.1–0.2 units/kg/day) and titrate
- Add prandial (bolus) insulin if postprandial hyperglycemia persists
Insulin Formulations
| Type | Onset | Peak | Duration |
|---|---|---|---|
| Rapid-acting (lispro, aspart) | 5–15 min | 30–90 min | 4–6 h |
| Short-acting (regular) | 30–60 min | 2–3 h | 8–10 h |
| Intermediate (NPH) | 2–4 h | 4–10 h | 10–16 h |
| Long-acting (glargine, detemir) | 2–4 h | No peak | 20–24 h |
| Ultra-long (degludec) | 1 h | No peak | > 42 h |
7. Monitoring
- Continuous Glucose Monitoring (CGM): Preferred for type 1 DM and type 2 DM on basal-bolus insulin; real-time glucose trends and alerts
- Self-monitored blood glucose (SMBG): Fingerstick; useful for type 2 on oral agents
- HbA1c: Reflects mean glucose over ~3 months; test every 3–6 months
- Time-in-Range (TIR): CGM-derived target > 70% of readings in 3.9–10 mmol/L range; < 4% below 3.9 mmol/L
8. Management of Comorbid Conditions
| Condition | Target/Intervention |
|---|---|
| Hypertension | < 130/80 mmHg; ACE inhibitor or ARB first-line (especially with CKD/proteinuria) |
| Dyslipidemia | High-intensity statin for all DM > 40 years or with CV risk; LDL-C < 1.8 mmol/L (< 70 mg/dL) if ASCVD |
| ASCVD | Aspirin 75–100 mg/day (for secondary prevention); GLP-1 RA or SGLT-2 inhibitor |
| CKD | SGLT-2 inhibitor + finerenone (if proteinuria); ACE/ARB; avoid nephrotoxic agents |
| Obesity | GLP-1 RA (semaglutide, tirzepatide); consider metabolic/bariatric surgery (BMI ≥ 35 or ≥ 30 with comorbidities) |
9. Special Situations
Hospitalized Patients
- Target glucose: 7.8–10 mmol/L (140–180 mg/dL) for most critically ill patients
- Use insulin infusion protocols (ICU) or basal-bolus subcutaneous regimens (non-ICU)
- Avoid sole use of sliding-scale insulin
Gestational DM
- First-line: lifestyle and dietary modification
- If targets not met: Insulin (preferred); metformin/glyburide as alternatives
- Targets: Fasting < 5.3 mmol/L; 1-h post-meal < 7.8; 2-h post-meal < 6.7 mmol/L
Elderly Patients
- Less stringent HbA1c goal (7.5–8.5%) to minimize hypoglycemia risk
- Avoid hypoglycemia-prone agents (long-acting sulfonylureas)
- Prefer agents with low hypoglycemia risk (DPP-4 inhibitors, GLP-1 RA)
10. Prevention of Complications
| Complication | Prevention Strategy |
|---|---|
| Retinopathy | Tight glycemic control; annual eye exam |
| Nephropathy | ACE/ARB; SGLT-2 inhibitor; BP control |
| Neuropathy | Glycemic control; foot care; annual monofilament exam |
| Cardiovascular | Statin; ACE/ARB; GLP-1 RA or SGLT-2 inhibitor; aspirin |
| Foot ulcers | Daily inspection; proper footwear; podiatry referral |
Key Take-Home Points:
- Management is individualized and multidisciplinary
- Metformin remains first-line for type 2 DM
- GLP-1 RAs and SGLT-2 inhibitors are preferred add-ons in patients with established ASCVD, HF, or CKD due to cardiovascular and renal outcome benefits
- CGM and closed-loop systems represent the current standard of care in type 1 DM
- Addressing comorbidities (BP, lipids, weight, psychosocial health) is as important as glucose control
— Harrison's Principles of Internal Medicine, 21e (Chapter 416); Tintinalli's Emergency Medicine, 9e (Chapter 115)
This is a shared conversation. Sign in to Orris to start your own chat.